Who are Ulimorelin Intravenously (IV)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RHB-102, MHOS/SHP615, KW-6500, Ulimorelin Invtravenously (IV).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ulimorelin-intravenously-iv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ulimorelin Intravenously (IV) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ulimorelin Intravenously (IV) (Ulimorelin Intravenously (IV)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ghrelin receptor agonist. Area: Gastroenterology.

phase 3 Ghrelin receptor agonist Ghrelin receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ulimorelin Intravenously (IV) (Ulimorelin Intravenously (IV)) — Tranzyme, Inc.. Ulimorelin is a ghrelin receptor agonist that stimulates gastric emptying.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ulimorelin Intravenously (IV) TARGET	Ulimorelin Intravenously (IV)	Tranzyme, Inc.	phase 3	Ghrelin receptor agonist	Ghrelin receptor
RHB-102	RHB-102	RedHill Biopharma Limited	phase 3	Gastric motility agent	Ghrelin receptor
MHOS/SHP615	MHOS/SHP615	Shire	phase 3	Growth hormone secretagogue	Ghrelin receptor (GHSR-1a)
KW-6500	KW-6500	Kyowa Kirin Co., Ltd.	phase 3	Growth hormone secretagogue	Ghrelin receptor (GHS-R1a)
Ulimorelin Invtravenously (IV)	Ulimorelin Invtravenously (IV)	Tranzyme, Inc.	phase 3	Ghrelin receptor agonist	Ghrelin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ghrelin receptor agonist class)

Tranzyme, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ulimorelin Intravenously (IV) — Competitive Intelligence Brief. https://druglandscape.com/ci/ulimorelin-intravenously-iv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing